PMC9992202_01
Clinical and pathological response. Images (A, B) show FDG uptake in the lung parenchyma. (C) CT images acquired after two circles of neoadjuvant tislelizumab plus chemotherapy display a decrease in the size of the tumor lesion. (D) Hematoxylin-eosin (HE) and immunohistochemistry staining in the tumor bed. The staining of the lung mass (lower panels) showed no viable tumor cells; negative for synaptophysin (Syn), pan-cytokeratin (PCK), and chromogranin A (CgA). Scale bars: D = 100 microm.
fimmu-14-1111325-g001.jpg
PMC9992202_01_fimmu-14-1111325-g001.jpg
f1
After two cycles of neoadjuvant treatment, a repeated CT scan manifested the mass obviously shrank to a nodule with a diameter of 0.8 cm ( Figure 1C ). A (CgA), and synaptophysin (Syn) ( Figure 1D ). After surgery, the patient received two cycles of tislelizumab in combination with etoposide-carboplatin.
Timeline from January 2021 to January 2023.
fimmu-14-1111325-g002.jpg
PMC9992202_01_fimmu-14-1111325-g002.jpg
f2
More than 23 months after neoadjuvant tislelizumab plus chemotherapy, no recurrence or metastases were detected ( Figure 2 ).